Yervoy®
Understanding Yervoy® (ipilimumab)
Yervoy® is a monoclonal antibody used in cancer immunotherapy to treat several types of advanced or metastatic cancers. It works by blocking CTLA-4 (Cytotoxic T-Lymphocyte Antigen-4), a protein that normally inhibits T-cell activation. By inhibiting CTLA-4, Yervoy® boosts the immune system’s ability to recognize and attack cancer cells.
How Yervoy® Works:
- Blocks CTLA-4, a protein that dampens immune response
- Enhances T-cell activation, allowing the immune system to attack cancer cells
- Improves long-term survival outcomes in certain cancers
FDA Approval:
- Yervoy® (ipilimumab): Approved on March 25, 2011, for the treatment of metastatic melanoma.
For more information, please visit the Yervoy® patient website and speak with your healthcare provider to determine if Yervoy® is the right treatment option for you.
Referral Form: |
MANUFACTURER: Bristol Myers Squibb (BMS) |
CLASS: CTLA-4 Inhibitor (Immune Checkpoint Inhibitor, Monoclonal Antibody) |
|
PRESCRIBED BY:
|
|
HOW ADMINISTERED: IV Infusion |
|
FREQUENCY: Every 3 to 6 weeks, depending on condition |
Length of infusion: About 60 mins |
FOR MORE INFORMATION: |
Related drugs
